Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement
Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinical development, CT-0508.
Carisma通知Novartis药品公司其终止制造和供应协议，该协议日期为2023年3月1日，涉及首个进入临床开发的产品候选制造CT-0508。
The termination is effective July 31, 2024. Pursuant to the Company's revised operating plan, the Company determined to focus its ex vivo oncology clinical development efforts on its follow-on product candidate CT-0525 and has suspended enrollment of new patients in its Phase 1 clinical trial for CT-0508.
终止日期为2024年7月31日。根据公司修订的运营计划，公司决定将重点放在其后续产品候选CT-0525的肿瘤临床开发上，并暂停招募CT-0508的一期临床试验的新患者。体外由于制造协议的终止，公司将承担等于400万美元的终止费用，预计将于2024年第三季度支付。
As a result of the termination of the Manufacturing Agreement, the Company will incur a termination fee equal to $4.0 million, which is expected to be paid in the third quarter of 2024.
由于制造协议的终止，公司将承担等于4.0百万美元的终止费用，预计将于2024年第三季度支付。